Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
Furuya
H
H
Laboratory of Molecular Carcinogenesis, NCI, NIH, Bethesda, MD 20892, USA.
Fernandez-Salguero
P
P
Gregory
W
W
Taber
H
H
Steward
A
A
Gonzalez
F J
FJ
Idle
J R
JR
D000483:Alleles; D000925:Anticoagulants / Q000008:administration & dosage* / Q000378:metabolism*; D001189:Aryl Hydrocarbon Hydroxylases; D001483:Base Sequence; D065729:Cytochrome P-450 CYP2C9; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics* / Q000378:metabolism*; D017931:DNA Primers / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D010597:Pharmacogenetics; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000235:genetics* / Q000378:metabolism*; D014859:Warfarin / Q000008:administration & dosage* / Q000378:metabolism*
D000925:Anticoagulants; D017931:DNA Primers; D014859:Warfarin; D003577:Cytochrome P-450 Enzyme System; D013250:Steroid Hydroxylases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D039181:Steroid 16-alpha-Hydroxylase